Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

8.84
+0.78509.75%
Volume:1.27M
Turnover:11.02M
Market Cap:583.56M
PE:-2.35
High:8.99
Open:8.14
Low:8.13
Close:8.06
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.78
T/O Rate:2.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:8.13
PE(LYR):-2.35

Loading ...

Regenxbio Seen on Track for Duchenne Approval as Data Strengthens, RBC Says

MT Newswires Live
·
Aug 08

Regenxbio Cut to Equal-Weight from Overweight by Barclays

Dow Jones
·
Aug 07

Morgan Stanley Adjusts Price Target on REGENXBIO to $18 From $16, Maintains Overweight Rating

MT Newswires Live
·
Aug 07

Regenxbio downgraded to Equal Weight from Overweight at Barclays

TIPRANKS
·
Aug 07

RegenXBio (RGNX) was downgraded to a Hold Rating at Barclays

TIPRANKS
·
Aug 07

Solid Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 07

Verastem Q2 Revenue Jumps on New Product Sales and Milestone

Reuters
·
Aug 07

Regenxbio Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Regenxbio Q2 Revenue Surges on AbbVie Milestone Payment

Reuters
·
Aug 06

Regenxbio Q2 FY26 Swings to Net Income of $22.71 Million; Revenue Climbs to $108.02 Million

Reuters
·
Aug 06

Regenxbio Q2 EPS $0.43 Beats $(0.03) Estimate, Sales $108.019M Miss $117.127M Estimate

Benzinga Earnings
·
Aug 06

Regenxbio Q2 Operating Expenses USD 78.756 Million

Reuters
·
Aug 06

Regenxbio Q2 License & Royalty Revenue USD 103.841 Million

THOMSON REUTERS
·
Aug 06

Regenxbio Inc Expected to Post Earnings of 6 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Regenxbio Schedules Conference Call to Discuss Second-Quarter Results and Operational Update

Reuters
·
Aug 03

Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and RegenXBio (RGNX)

TIPRANKS
·
Aug 03

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Benzinga_recent_news
·
Jul 22

Regenxbio presents long-term data for surabgene lomparvovec

TIPRANKS
·
Jul 19

Regenxbio Presents Positive Long-term Data for Surabgene Lomparvovec in Wet Amd and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

THOMSON REUTERS
·
Jul 19

Regenxbio Reports 5-year Wet AMD Efficacy Data for Sura-vec Gene Therapy at ASRS Meeting

Reuters
·
Jul 19